Antimicrobial Peptides Guide: LL-37, Defensins, Mechanisms, and Biofilm Disruption

Antimicrobial peptides (AMPs) are ancient components of the innate immune system found in virtually every living organism — from insects and frogs to humans. They are among the body's first responders to infection, acting within minutes to kill bacteria, fungi, and viruses. As antibiotic resistance has emerged as a global health crisis, AMPs have attracted enormous research attention as potential next-generation antimicrobials. Understanding how they work — and how they might be leveraged therapeutically — is increasingly relevant for both conventional medicine and research into chronic infections.

What Are Antimicrobial Peptides?

AMPs are short peptides, typically 10–50 amino acids in length, that are cationic (positively charged) and amphipathic (having both water-loving and water-repelling regions). These properties allow them to interact selectively with microbial membranes, which carry a net negative charge — in contrast to mammalian cell membranes, which are largely neutral.

The human AMP arsenal includes:

• Cathelicidins: Represented in humans by a single member, LL-37
• Alpha-defensins: Produced by neutrophils and intestinal Paneth cells (HNP-1 through HNP-4, HD-5, HD-6)
• Beta-defensins: Produced by epithelial cells throughout the body (HBD-1 through HBD-4 and beyond)
• Histatins: Salivary AMPs with antifungal activity
• Dermcidin: Produced in sweat glands

LL-37: The Human Cathelicidin

LL-37 is the most studied human AMP and the only human cathelicidin. It is produced by neutrophils, epithelial cells, monocytes, and NK cells — essentially wherever the body interfaces with the external environment.

Structure and activity: LL-37 adopts an alpha-helical structure when it contacts bacterial membranes. This helical form inserts into the lipid bilayer, forming pores or disrupting membrane integrity. The result is rapid bacterial death through membrane depolarization, cytoplasmic leakage, and inhibition of intracellular targets.

Spectrum of activity: LL-37 is active against:

• Gram-negative bacteria (E. coli, Pseudomonas, Klebsiella, H. pylori)
• Gram-positive bacteria (Staphylococcus aureus, including MRSA)
• Fungi (Candida species)
• Enveloped viruses (influenza, HIV, respiratory syncytial virus)
• Parasites (Leishmania)

Beyond direct killing: LL-37 is also an immunomodulator. It activates dendritic cells, enhances phagocytosis by macrophages, promotes wound healing, and modulates inflammatory signaling through multiple receptor pathways including TLR4 and FPRL1. This dual role — direct microbicidal plus immunomodulatory — makes it distinct from conventional antibiotics.

Our dedicated LL-37 peptide guide covers the full research profile including supplementation strategies.

Defensins: Epithelial and Neutrophil Defense

Defensins are the largest family of human AMPs. They are divided into alpha- and beta-defensins based on the positions of their disulfide bonds.

Alpha-defensins (HNPs): Human neutrophil peptides (HNP-1 through 4) are stored in azurophilic granules of neutrophils and released upon activation. They are potently bactericidal and also have significant antifungal and antiviral activity. Intestinal alpha-defensins HD-5 and HD-6, produced by Paneth cells, are critical guardians of gut microbial balance — reduced HD-5 expression has been linked to Crohn's disease and IBS.

Beta-defensins (HBDs): These are produced constitutively or inducibly by epithelial cells in the skin, respiratory tract, gastrointestinal tract, and genitourinary tract. HBD-1 is constitutively expressed; HBD-2 and HBD-3 are strongly upregulated by infection and inflammation. HBD-3 is particularly potent against MRSA and other antibiotic-resistant organisms.

Immunomodulatory roles: Defensins also recruit dendritic cells and T cells through chemotaxis, bridging the innate and adaptive immune responses. This makes them more than simple antimicrobials — they are coordinators of the immune response.

Mechanisms of Antimicrobial Action

AMPs kill microorganisms through several complementary mechanisms:

Membrane disruption: The primary mechanism. Cationic AMPs electrostatically attract to negatively charged microbial membranes, then insert and disrupt bilayer integrity through:

• Barrel-stave model: Peptides form transmembrane channels
• Carpet model: Peptides coat the membrane and cause detergent-like dissolution
• Toroidal pore model: Peptides create pores that include both peptide and lipid components

Intracellular targets: Some AMPs penetrate inside bacteria and inhibit:

• DNA/RNA synthesis
• Protein synthesis (ribosomal interference)
• Cell wall synthesis
• Enzymatic activity

Immunomodulation: Many AMPs reduce excessive inflammatory signaling (limiting tissue damage) while enhancing pathogen clearance — a dual function with therapeutic implications.

Biofilm Disruption: A Critical Advantage Over Antibiotics

Perhaps the most clinically significant advantage of AMPs over conventional antibiotics is their effectiveness against bacterial biofilms. Biofilms are structured communities of bacteria enclosed in a self-produced matrix, often attached to surfaces — including medical devices, dental surfaces, and chronically infected tissues.

Bacteria in biofilms are up to 1,000 times more resistant to conventional antibiotics than planktonic (free-floating) bacteria. This is a major reason why chronic infections — including chronic Lyme disease, prosthetic joint infections, and recurrent UTIs — are so difficult to eradicate.

How AMPs disrupt biofilms:

• LL-37 disrupts the quorum sensing signals bacteria use to coordinate biofilm formation
• AMPs penetrate the extracellular matrix (ECM) of biofilms more effectively than hydrophilic antibiotics
• Certain AMPs degrade the polysaccharide components of biofilm matrices
• The multi-mechanism killing of AMPs means biofilm bacteria cannot develop resistance through a single mutation

Applications in Lyme Disease and Chronic Infections

Borrelia burgdorferi, the bacterium causing Lyme disease, is known to form biofilms and can enter a dormant "persister" state that evades both antibiotics and the immune system. This is thought to contribute to persistent symptoms in some patients after antibiotic treatment.

AMPs, particularly LL-37, are of research interest for Lyme because:

• LL-37 has demonstrated direct bactericidal activity against Borrelia in vitro
• LL-37 disrupts Borrelia biofilms at concentrations achievable in vivo
• Immune evasion by Borrelia includes downregulation of LL-37 and defensin expression
• Restoring AMP activity may improve clearance of persistent forms

For a detailed review of peptide applications in Lyme disease coinfections, see our peptides for Lyme coinfections guide.

AMP Resistance: The Emerging Challenge

Unlike conventional antibiotics, bacteria develop resistance to AMPs much more slowly. This is because:

• AMPs target fundamental membrane properties, not specific protein targets
• Multiple simultaneous mechanisms of action reduce the chance of resistance-conferring mutations

However, resistance is not impossible. Some bacteria modify their membrane charge, produce proteases that degrade AMPs, or form biofilms as a resistance strategy. Monitoring for resistance development is important as AMPs move toward clinical use.

Therapeutic Development Status

Multiple AMP-derived drugs are in clinical development:

• Pexiganan (MSI-78): A synthetic magainin analog, studied for diabetic foot ulcer infections
• Omiganan: Studied for catheter-site infections and rosacea
• Brilacidin: A defensin-mimetic studied for acute bacterial skin infections
• LL-37 derivatives: Engineered for improved stability and activity, in early-phase trials for wound infections

The main challenges for AMP therapeutics are: stability in the systemic circulation (proteolytic degradation), potential cytotoxicity at high doses, and manufacturing costs.

Lifestyle Factors That Support Endogenous AMP Production

Research shows that LL-37 and defensin production can be supported through natural means:

• Vitamin D: Is the most established inducer of LL-37 expression — vitamin D receptor (VDR) response elements are present in the LL-37 gene promoter. Vitamin D deficiency is strongly associated with reduced LL-37 production and increased infection susceptibility
• Exercise: Moderate exercise increases LL-37 production in epithelial cells
• Short-chain fatty acids: Butyrate (produced by fiber-fermenting gut bacteria) induces defensin and LL-37 expression in intestinal epithelial cells

Frequently Asked Questions

Q: Are antimicrobial peptides safe for human use? Endogenous AMPs like LL-37 and defensins are produced naturally by the human body and are generally well-tolerated. Exogenous supplementation or therapeutic AMP administration is still in the research/early clinical phase for most applications. Systemic toxicity is a concern at high doses, which is why most therapeutic applications focus on topical or localized delivery.

Q: How do AMPs differ from traditional antibiotics? Traditional antibiotics typically target a single bacterial protein or pathway (e.g., cell wall synthesis, ribosome). AMPs primarily target the bacterial membrane — a fundamental physical structure — using multiple simultaneous mechanisms. This makes resistance development much harder and allows AMPs to kill antibiotic-resistant organisms.

Q: Can low vitamin D cause recurrent infections? Yes. Vitamin D is required for LL-37 expression in epithelial cells and macrophages. Multiple epidemiological studies link vitamin D deficiency to increased susceptibility to respiratory, urinary, and skin infections — conditions where LL-37 is a critical first-line defense.

Q: What is the connection between gut health and AMPs? Paneth cells in the small intestine produce high concentrations of alpha-defensins (HD-5 and HD-6) that maintain the gut microbiome composition. Reduced Paneth cell function — seen in Crohn's disease and other gut disorders — leads to defensin deficiency and microbiome dysbiosis. This is one mechanism linking gut inflammation to infection susceptibility.

Q: How is LL-37 administered in research settings? LL-37 is administered topically for wound and skin applications, intranasally for respiratory applications, and subcutaneously or intravenously in systemic research contexts. Oral administration degrades LL-37 rapidly in the GI tract, limiting systemic bioavailability by this route, though there may be local gut effects.